Category: Allergan Inc.
New Jersey governor Chris Christie's revelation this week that he had LAP-BAND procedure for weight loss hightlights the power of celebrity endorsements for medical procedures
When the New York Post broke the story this week that New Jersey governor and presidential hopeful Chris Christie had underwent weight loss surgery using the LAP-BAND in February some on Wall Street bemoaned the rotund politicians timing.
New Jersey Gov. Chris Christie (R) revealed this week that he secretly had gastric banding surgery for weight loss.
MASSDEVICE ON CALL — New Jersey Governor Chris Christie (R) underwent secret Lap-Band surgery to help him lose weight, he revealed to the New York Post this week.
Some analysts suggested that the move signals that Christie is looking at a run for the White House, but the Christie, how has come under fire for his physique on more than 1 occasion, insisted that the surgery was prompted by concern for his health and the urging of his family.
Aesthetics products maker Allergan may be poised to take a larger piece of the facial filler market should the FDA approve its Juvederm Voluma XC injectable gel.
Aesthetics products giant Allergan (NYSE:AGN) is poised to add another 1st to its repertoire, as long as U.S. healthcare regulators green-light the company's Juvederm Voluma XC injectable gel for volume restoration in the mid-face.
Shares of medical aesthetics giant Allergan initially drop 13% on its Q1 results and a lowered earnings forecast, with shares rebounding toward the end of the week.
Allergan (NYSE:AGN) took a ride on the wild side this week as Wall Street pounded the medical aesthetics company after its 1st-quarter earnings release, initially sending share down more than 13%.
Some of the selloff appeared related to news that Irvine, Calif.-based Allergan is delaying the rollout of Darpin, its macular degeneration drug. Investors were also spooked by lowered guidance for 2013 and a bottom-line writedown over the sale of its Lap-Band business.
The FDA's General & Plastic Surgery Devices advisory panel votes unanimously that the benefits outweigh the risks for aesthetic medical device maker Allergan's Juvederm Voluma XC injectable gel.
An FDA advisory panel voted today to recommend approval for Allergan's (NYSE:AGN) Juvederm Voluma XC dermal filler for aesthetic volume restoration in the mid-face.
The FDA's General & Plastic Surgery Devices advisory panel unanimously decided that the injectable gel is safe, effective and that its benefits outweigh its risks.
MassDevice.com looks at the internet chatter surrounding the medical device industry with some of most searched-for companies of the last month.
MassDevice.com looked at some of the most talked-about medical device companies, based on trends in U.S. Google searches for the last 30 days.
Aesthetics giant Allergan wins a panel date with the FDA for review of its Juv[eacute]derm Voluma XC dermal filler.
MASSDEVICE ON CALL — Aesthetic medical device maker Allergan (NYSE:AGN) will get a date with the FDA to review clinical data for the company's Juv[eacute]derm Voluma XC dermal filler.
Allergan hopes to win indication for deep implantation for aesthetic restoration in the face, according to the FDA notice.